P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS

• Danny Jeyaraju,
• Sheida Hayati,
• Ann Polonskaia,
• Andrew Browne,
• Alberto Risueño,
• Patrick Hagner,
• Vikas Gupta,
• Moshe Talpaz,
• Christopher Hernandez,
• Vincent Chia,
• Patrick Brown,
• Daniel Lopes De Menezes,
• Ross La Motte-Mohs,
• Rajasekhar Nvs Suragani,
• Anita Gandhi

Affiliations

Danny Jeyaraju

1 Bristol Myers Squibb, Summit, United States

Sheida Hayati

2 Bristol Myers Squibb, Princeton, United States

Ann Polonskaia

1 Bristol Myers Squibb, Summit, United States

Andrew Browne

3 Bristol Myers Squibb, Cambridge, United States

Alberto Risueño

2 Bristol Myers Squibb, Princeton, United States

Patrick Hagner

1 Bristol Myers Squibb, Summit, United States

Vikas Gupta

4 Princess Margaret Cancer Center, Toronto, Canada

Moshe Talpaz

5 University of Michigan, Ann Arbor, United States

Christopher Hernandez

1 Bristol Myers Squibb, Summit, United States

Vincent Chia

1 Bristol Myers Squibb, Summit, United States

Patrick Brown

2 Bristol Myers Squibb, Princeton, United States

Daniel Lopes De Menezes

6 Bristol Myers Squibb, San Francisco, United States

Ross La Motte-Mohs

1 Bristol Myers Squibb, Summit, United States

Rajasekhar Nvs Suragani

3 Bristol Myers Squibb, Cambridge, United States

Anita Gandhi

1 Bristol Myers Squibb, Summit, United States